ArticleBirth defects research2026
Nonclinical Considerations for Support of Pregnancy and Lactation in Clinical Trials.
Article in Birth defects research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Developmental Toxicity Study for the Antimalarial Drug Combination Cabamiquine-Pyronaridine Using a Translational Approach.Birth defects research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPregnant and breastfeeding individuals remain underrepresented in clinical drug development, leaving health care providers and patients with limited data to inform treatment decisions. Current practice relies heavily on nonclinical developmental and reproductive toxicity (DART) studies in animals, while clinical trials typically exclude pregnant and breastfeeding populations or require highly effective contraception for women of childbearing potential. Consequently, medications may be used during pregnancy or lactation despite limited supporting evidence, which can lead to treatment interruption, suboptimal dosing, and increased maternal or fetal risk. Emerging regulatory guidance, including draft ICH Guideline on Inclusion of Pregnant and Breastfeeding Individuals in Clinical Trials (E21), highlights the ethical and clinical need to generate data directly in these populations.
methodsThis paper evaluates the current regulatory framework for nonclinical studies described in ICH S5(R3) and M3(R2) and examines how these studies can support the enrollment of pregnant and breastfeeding individuals in clinical trials. It proposes pragmatic adaptations to align nonclinical testing with the anticipated clinical context of use and considers the role of new approach methodologies (NAMs) and alternative study designs.
resultsPotential DART strategies are described that could enable the inclusion of pregnant individuals in clinical trials based on factors such as dosing duration, route of administration, and study type (e.g., pharmacokinetic studies). The paper also considers the use of NAMs, including physiologically based pharmacokinetic modeling and in vitro assays, as well as alternative study designs such as preliminary pre- and postnatal development or extended embryo-fetal development studies. Approaches to inform studies in breastfeeding populations, including milk-plasma ratio modeling and translation from nonclinical data, are also discussed.
conclusionsThese approaches support a shift from routine exclusion toward proactive and ethical inclusion of pregnant and breastfeeding individuals in clinical research, helping address longstanding evidence gaps and improving therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.